JP2016501189A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501189A5 JP2016501189A5 JP2015541933A JP2015541933A JP2016501189A5 JP 2016501189 A5 JP2016501189 A5 JP 2016501189A5 JP 2015541933 A JP2015541933 A JP 2015541933A JP 2015541933 A JP2015541933 A JP 2015541933A JP 2016501189 A5 JP2016501189 A5 JP 2016501189A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- pharmaceutical composition
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261724266P | 2012-11-08 | 2012-11-08 | |
| US61/724,266 | 2012-11-08 | ||
| PCT/US2013/069193 WO2014074848A1 (en) | 2012-11-08 | 2013-11-08 | Therapeutic compounds and compositions and their use as pkm2 modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501189A JP2016501189A (ja) | 2016-01-18 |
| JP2016501189A5 true JP2016501189A5 (enExample) | 2016-12-22 |
| JP6362610B2 JP6362610B2 (ja) | 2018-07-25 |
Family
ID=49667584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015541933A Expired - Fee Related JP6362610B2 (ja) | 2012-11-08 | 2013-11-08 | 治療用化合物及び組成物並びにｐｋｍ２調節剤としてのそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9458132B2 (enExample) |
| EP (1) | EP2917207A1 (enExample) |
| JP (1) | JP6362610B2 (enExample) |
| KR (1) | KR20150080619A (enExample) |
| CN (1) | CN104822672B (enExample) |
| AU (1) | AU2013342203B2 (enExample) |
| CA (1) | CA2890664A1 (enExample) |
| EA (1) | EA032007B1 (enExample) |
| HK (1) | HK1213888A1 (enExample) |
| MX (1) | MX2015005841A (enExample) |
| NZ (1) | NZ707778A (enExample) |
| WO (1) | WO2014074848A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2909181B1 (en) | 2012-10-16 | 2017-08-09 | Tolero Pharmaceuticals, Inc. | Pkm2 modulators and methods for their use |
| US9353122B2 (en) | 2013-02-15 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9353123B2 (en) | 2013-02-20 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| KR20160099084A (ko) | 2013-11-01 | 2016-08-19 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정질 형태 및 그의 용도 |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CN104817490B (zh) * | 2015-05-13 | 2017-10-13 | 北京大学 | 氨基二硫代甲酸酯类化合物及其制备方法与应用 |
| WO2017095751A1 (en) | 2015-12-02 | 2017-06-08 | Partikula Llc | Compositions and methods for modulating cancer cell metabolism |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| WO2018048750A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| AR111295A1 (es) * | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| EP3668513B1 (en) | 2017-08-15 | 2021-11-10 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in treating blood disorders |
| US20200237766A1 (en) | 2017-10-13 | 2020-07-30 | Tolero Pharmaceuticals, Inc. | Pkm2 activators in combination with reactive oxygen species for treatment of cancer |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| WO2020172075A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| AU2020245437A1 (en) | 2019-03-22 | 2021-09-30 | Sumitomo Pharma Oncology, Inc. | Compositions comprising PKM2 modulators and methods of treatment using the same |
| MX2022003025A (es) | 2019-09-19 | 2022-04-07 | Forma Therapeutics Inc | Activacion de la piruvato cinasa r. |
| WO2022170200A1 (en) | 2021-02-08 | 2022-08-11 | Global Blood Therapeutics, Inc. | 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3545461B2 (ja) | 1993-09-10 | 2004-07-21 | エーザイ株式会社 | 二環式ヘテロ環含有スルホンアミド誘導体 |
| US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
| CZ2002773A3 (cs) | 1999-09-04 | 2002-06-12 | Astrazeneca Ab | Substituované deriváty N-fenyl-2-hydroxy-2-methyl-3,3,3-trifluorpropanamidu, které zvyąují aktivitu pyruvátdehydrogenázy |
| JP2008514590A (ja) | 2004-09-24 | 2008-05-08 | アストラゼネカ・アクチエボラーグ | ベンゾイミダゾール誘導体、それを含む組成物、その製造方法及びその使用 |
| ES2620634T3 (es) * | 2008-10-09 | 2017-06-29 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Activadores de piruvato quinasa humana |
| CN102985557B (zh) | 2009-03-13 | 2018-06-15 | 安吉奥斯医药品有限公司 | 用于细胞增殖相关病症的方法和组合物 |
| JP5756457B2 (ja) * | 2009-04-06 | 2015-07-29 | アジオス ファーマシューティカルズ， インコーポレイテッド | ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法 |
| AU2010239188B2 (en) | 2009-04-22 | 2016-03-31 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| DK2448581T3 (en) * | 2009-06-29 | 2017-03-13 | Agios Pharmaceuticals Inc | Therapeutic compositions and methods for their applications |
| PE20120693A1 (es) * | 2009-06-29 | 2012-07-04 | Agios Pharmaceuticals Inc | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) |
| US20130109672A1 (en) * | 2010-04-29 | 2013-05-02 | The United States Of America,As Represented By The Secretary, Department Of Health And Human Service | Activators of human pyruvate kinase |
| DE102010048800A1 (de) | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | Chinoxalinderivate |
| US9221792B2 (en) * | 2010-12-17 | 2015-12-29 | Agios Pharmaceuticals, Inc | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators |
| TWI549947B (zh) * | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| US9388164B2 (en) * | 2011-05-03 | 2016-07-12 | Agios Pharmaceuticals, Inc | Methods of using pyruvate kinase activators |
| PT3406251T (pt) * | 2011-05-03 | 2024-01-24 | Agios Pharmaceuticals Inc | Ativadores da piruvato-cinase para utilização em terapia |
-
2013
- 2013-11-08 NZ NZ707778A patent/NZ707778A/en not_active IP Right Cessation
- 2013-11-08 KR KR1020157014747A patent/KR20150080619A/ko not_active Withdrawn
- 2013-11-08 US US14/441,746 patent/US9458132B2/en not_active Expired - Fee Related
- 2013-11-08 JP JP2015541933A patent/JP6362610B2/ja not_active Expired - Fee Related
- 2013-11-08 WO PCT/US2013/069193 patent/WO2014074848A1/en not_active Ceased
- 2013-11-08 EP EP13795929.2A patent/EP2917207A1/en not_active Withdrawn
- 2013-11-08 HK HK16101847.5A patent/HK1213888A1/zh unknown
- 2013-11-08 MX MX2015005841A patent/MX2015005841A/es unknown
- 2013-11-08 CN CN201380063407.2A patent/CN104822672B/zh not_active Expired - Fee Related
- 2013-11-08 CA CA2890664A patent/CA2890664A1/en not_active Abandoned
- 2013-11-08 AU AU2013342203A patent/AU2013342203B2/en not_active Ceased
- 2013-11-08 EA EA201590881A patent/EA032007B1/ru not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512203A5 (enExample) | ||
| JP2017527561A5 (enExample) | ||
| JP2010524942A5 (enExample) | ||
| EA201391029A1 (ru) | Производные оксазина и их применение при лечении неврологических нарушений | |
| JP2013533879A5 (enExample) | ||
| CA2683956A1 (en) | Quinolones and azaquinolones that inhibit prolyl hydroxylase | |
| RU2015126015A (ru) | Новые улавливатели в лечении макулодистрофии | |
| JP2015504067A5 (enExample) | ||
| JP2020531443A5 (enExample) | ||
| CN105209036B (zh) | 氧杂双环庚烷和氧杂双环庚烯的配制品 | |
| EA201200176A1 (ru) | Производные оксазина и их применение для лечения неврологических нарушений | |
| JP2017514809A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
| JP2017517556A5 (enExample) | ||
| JP2011006480A5 (enExample) | ||
| JP2015501833A5 (enExample) | ||
| JP2015518008A5 (enExample) | ||
| EA201290906A1 (ru) | Кристаллогидратные формы n-[3-фтор-4-({6-(метилокси)-7-[(3-морфолин-4-илпропил)окси]хинолин-4-ил}окси)фенил]-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида | |
| JP2015500842A5 (enExample) | ||
| MY198292A (en) | Novel Phenyl Propionic Acid Derivatives and uses Thereof | |
| JP2016516074A5 (enExample) | ||
| JP2020527173A5 (enExample) | ||
| JP2023550591A5 (enExample) | ||
| JP2020515645A5 (enExample) |